FDAnews Drug Daily Bulletin
Pharmaceuticals / Regulatory Affairs

FDA Policy Roadmap Targets Opioid Addiction, Strengthening Generic Competition

Jan. 17, 2018

The FDA will prioritize the opioid crisis, innovation, and generic competition in the coming year, the agency said in a 2018 Strategic Policy Roadmap released Thursday.

Tackling the opioid addiction crisis will continue as a major policy priority, including increased efforts to help patients secure medication-assisted treatments and to reduce the stigma attached to them, the agency said.

On the clinical side, the FDA will work to help steer the market toward opioid formulations that are harder to manipulate or abuse as well as incentivize creating pain treatments that are less likely to result in addiction.

View today's stories